May 2007
Volume 48, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2007
Intravitreal Bevacizumab (Avastin) in Combination With Verteporfin Photodynamic Therapy for Choroidal Neovascularization Associated With Age-Related Macular Degeneration (IBeVe Study)
R. A. Costa; R. Jorge; D. Calucci; L. A. S. Melo, Jr.; L. Paccola; J. A. Cardillo; I. U. Scott
Author Affiliations & Notes
  • R. A. Costa
    Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
    Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
  • R. Jorge
    Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
  • D. Calucci
    Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • L. A. S. Melo, Jr.
    Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • L. Paccola
    Department of Ophthalmology, School of Medicine of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil
  • J. A. Cardillo
    Macular Imaging & Treatment Division, Hospital de Olhos de Araraquara, Araraquara, Brazil
  • I. U. Scott
    Departments of Ophthalmology and Health Evaluation Sciences, Penn State College of Medicine, Hershey, Pennsylvania
  • Footnotes
    Commercial Relationships R.A. Costa, None; R. Jorge, None; D. Calucci, None; L.A.S. Melo, None; L. Paccola, None; J.A. Cardillo, None; I.U. Scott, None.
  • Footnotes
    Support None.
Investigative Ophthalmology & Visual Science May 2007, Vol.48, 3379. doi:
  • Views
  • Share
  • Tools
    • Alerts
      User Alerts
      You are adding an alert for:
      Intravitreal Bevacizumab (Avastin) in Combination With Verteporfin Photodynamic Therapy for Choroidal Neovascularization Associated With Age-Related Macular Degeneration (IBeVe Study)
      You will receive an email whenever this article is corrected, updated, or cited in the literature. You can manage this and all other alerts in My Account
      The alert will be sent to:
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation
      Citation

      R. A. Costa, R. Jorge, D. Calucci, L. A. S. Melo, Jr., L. Paccola, J. A. Cardillo, I. U. Scott; Intravitreal Bevacizumab (Avastin) in Combination With Verteporfin Photodynamic Therapy for Choroidal Neovascularization Associated With Age-Related Macular Degeneration (IBeVe Study). Invest. Ophthalmol. Vis. Sci. 2007;48(13):3379.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

      ×
    • Get Permissions
  • Supplements
Abstract

Purpose:: To investigate the effects of intravitreal bevacizumab when combined with verteporfin photodynamic therapy (PDT) for the treatment of choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

Methods:: Prospective open-label study of 11 patients with documented CNV progression after one or two treatment sessions of PDT who underwent combined PDT and intravitreal injection of 1.5mg of bevacizumab. Standardized ophthalmic evaluation was performed at baseline and at weeks 1, 2, 12 and 24. Clinical evidence of complications as well as changes in best-corrected visual acuity (BCVA) and in fluorescein leakage from CNV were evaluated.

Results:: The mean baseline logarithm of the minimum angle of resolution (logMAR) Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA was 1.031 (20/200-2). At follow-up weeks 1, 2, 12 and 24, the mean logMAR ETDRS BCVA was 0.944 (20/160-2), 0.924 (20/160-1), 0.882 (20/160+1), and 0.933 (20/160-2), respectively. The change in BCVA from baseline was significant at each study follow-up interval (P < 0.001); at 12 and 24 weeks, the mean change in BCVA from baseline was an improvement of 1.49 and of 0.98 ETDRS line, respectively. Fluorescein leakage from CNV was absent in all eyes at week-12. One additional treatment session was required in seven (63.6%) eyes at week-24 due to recurrence of some fluorescein leakage (minimum, n=4; moderate, n=3) from CNV. No progression of the neovascular lesion was observed throughout the study.

Conclusions:: The overall changes observed in vision and fluorescein leakage from CNV throughtout the study suggest that a possible synergistic effect may arise from the combination of intravitreal bevacizumab with PDT for the treatment of neovascular AMD.

Keywords: age-related macular degeneration • choroid: neovascularization • photodynamic therapy 
© 2007, The Association for Research in Vision and Ophthalmology, Inc., all rights reserved. Permission to republish any abstract or part of an abstract in any form must be obtained in writing from the ARVO Office prior to publication.
Copyright © 2024 Association for Research in Vision and Ophthalmology.
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×
This site uses cookies. By continuing to use our website, you are agreeing to our privacy policy.Accept